Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AlpN GBS vaccine
- Development stage
- Unknown
- Lead developer
- Minervax
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AlpN GBS vaccine (also known as GBS-NN/NN2) is a novel recombinant protein subunit vaccine developed by MinervaX for the prevention of Group B Streptococcus (GBS) infections. The vaccine is designed for maternal immunization to protect newborns via passive transfer of maternal IgG antibodies, as well as for the active immunization of older adults who are at increased risk of invasive GBS disease. Unlike traditional capsular polysaccharide conjugate vaccines, AlpN GBS is based on fusions of highly immunogenic N-terminal domains from the GBS Alpha-like protein (Alp) family, specifically Alpha C (AlpC), Rib, Alp1, and Alp2/3. This protein-only formulation is adjuvanted with aluminum hydroxide (Alhydrogel) and is designed to provide broad protection against virtually all circulating GBS strains.
- Other names
- AlpN GBSAlpN-GBS vaccineGroup B Streptococcus-NN/NN2Group B Streptococcus-NN/NN2 vaccinematernal AlpN-GBS vaccine
02
Targets
Group B Streptococcus alpha-like protein N-terminal domain
Beyond the preview
Go deeper on AlpN GBS vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlpN GBS vaccine.